OnKure Therapeutics Inc. (Nasdaq: OKUR)
The University of Colorado Connection
OnKure Therapeutics is a publicly traded, Boulder-based clinical-stage biopharmaceutical company focused on developing best-in-class precision medicines for cancer. Its lead program, OKI-219, is a selective PI3KαH1047R inhibitor currently in clinical trials, with additional programs in development targeting other oncogenic mutations within the PI3K pathway. OnKure was co-founded by Ìý(ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ Biochemistry), and its origins are closely connected to CU-based research. Liu continues his innovation at CU with additional startups and preclinical assets in development.
Funding Status and Investment Opportunities
- Industry Applications: Health and Wellness, Biotech​, Therapeutics
- Funding Stage: Publicly traded—OKUR
Technology Development Funding
U.S. National Institutes of Health (NIH)
ÌýÌý ÌýThis page was last updated on April 3, 2025. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor eNewsletter
Media Inquiries
For marketing inquiries and news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ.
For media inquiries, please visit .